

HOUSE OF JANE INC.

a Nevada corporation

1 N. 1 St., #654

Phoenix, AZ 85004

Telephone: (602) 688-9981

Website: www.hojinc.com

Email: info@hojinc.com

SIC Code: 5149



Quarterly Report

For the period ending May 31, 2026
(the "Reporting Period")

Outstanding Shares

The number of shares outstanding of our Common Stock was:

11,031,895 as of July 13, 2026 (Current Reporting Date or More Recent Date)

11,031,895 as of November 30, 2025 (Most Recent Completed Fiscal Year End)

Shell Status

Indicate by a check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: ☐ No: ☒

Indicate by a check mark whether Issuer's shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

Change in Control

Indicate by a check mark whether a change in control has occurred over the reporting period:

Yes: ☐ No: ☒

1) Name and address(es) of the issuer and its predecessors (if any)

Provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes:

House of Jane Inc., January 9, 2019. Predecessor: VT Business Products, Inc., September 3, 2004 (date of inception) until January 9, 2019. Plan of Domestication filed January 9, 2019 to change domicile from Arizona to Nevada and change name from VT Business Products, Inc. to House of Jane Inc.

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g., active, default, inactive):

Issuer: Nevada corporation, January 9, 2019. Registration No. 20190011310-98. Active. Predecessor: Arizona corporation, September 3, 2004 (date of inception) until January 9, 2019. Registration No. 1152198-9. Merged out pursuant to Plan of Domestication filed January 9, 2019.

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

None.

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None.

The address(es) of the issuer's principal executive office:

1 N. 1 St., #654
Phoenix, AZ 85004

The address(es) of the issuer's principal place of business:

☒ Check if principal executive office and principal place of business are the same address:

Has the Issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: ☐ No: ☒ If yes, provide additional details below:

2) Security Information

Transfer agent

Nevada Agency and Transfer Company
(775) 322-0626
stocktransfer@natco.com
50 West Liberty Street, Suite 880
Reno, NV 89501

Publicly Quoted or Traded Securities:

Trading symbol: HOJI

Exact title and class of securities outstanding: Common

CUSIP: 44177J 202

Par or stated value: \$.001 per share.

Total shares authorized: 190,000,000 as of January 9, 2019 to present.

Total shares outstanding: 11,031,895 as of May 31, 2026.

Total number of shareholders of record: 285 as of May 31, 2026.

All additional class(es) of publicly quoted or traded securities (if any): None.

Other classes of authorized or outstanding equity securities:

Exact title and class of securities outstanding: Preferred stock

CUSIP: N/A

Par or stated value: \$.001 per share.

Total shares authorized: 10,000,000 as of January 9, 2019 to present.

Total shares outstanding: -0- as of May 31, 2026.

Total number of shareholders of record: -0- as of May 31, 2026.

Exact title and class of securities outstanding: Series A Warrant

CUSIP: 44177J 129

Exercise price: \$4.00 per share

Total Series A Warrants outstanding: 2,923,743 as of May 31, 2026

Expiration date: August 31, 2026

Total number of shareholders of record: -0- as of May 31, 2026.

Exact title and class of securities outstanding: Series B Warrant

CUSIP: 44177J 137

Exercise price: \$4.00 per share

Total Series B Warrants outstanding: 4,211,782 as of May 31, 2026

Expiration date: August 31, 2026

Total number of shareholders of record: -0- as of May 31, 2026.

Exact title and class of securities outstanding: Series C Warrant

CUSIP: 44177J 145

Exercise price: \$6.00 per share

Total Series C Warrants outstanding: 4,211,782 as of May 31, 2026

Expiration date: August 31, 2026

Total number of shareholders of record: -0- as of May 31, 2026.

Trading symbol: N/A

Exact title and class of securities outstanding: Series D Warrant

CUSIP: 44177J 152

Exercise price: \$6.00 per share

Total Series D Warrants outstanding: 4,211,782 as of May 31, 2026

Expiration date: August 31, 2026

Total number of shareholders of record: -0- as of May 31, 2026.

Trading symbol: N/A

Exact title and class of securities outstanding: Series E Warrant

CUSIP: 44177J 160

Exercise price: \$8.00 per share

Total Series E Warrants outstanding: 4,211,782 as of May 31, 2026

Expiration date: August 31, 2026

Total number of shareholders of record: -0- as of May 31, 2026.

Trading symbol: N/A

Exact title and class of securities outstanding: Series F Warrant

CUSIP: 44177J 178

Exercise price: \$8.00 per share

Total Series F Warrants outstanding: 4,211,782 as of May 31, 2026

Expiration date: August 31, 2026

Total number of shareholders of record: -0- as of May 31, 2026.

Security Description:

Provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:

1. For common equity, describe any dividend, voting and preemption rights.

The Issuer's authorized capital consists of 190,000,000 shares of common stock, \$.001 par value per share.

2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.

The Issuer's authorized capital consists of 10,000,000 shares of undesignated preferred stock. The board of directors, in its sole discretion, may establish par value, divide the shares of preferred stock into series, and fix and determine the dividend rate, designations, preferences, privileges, and ratify the powers, if any, and determine the restrictions and qualifications of

any series of preferred stock as established. No series of preferred stock have been designated.

3. Describe any other material rights of common or preferred stockholders.

None.

4. Describe any material modifications to the rights of holders of the company's securities that have occurred over the reporting period covered by this report.

None.

3) Issuance History

Provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the Issuer's securities in the past two completed fiscal years and any subsequent interim period.

None.

A. Changes to the Number of Outstanding Shares for the two most recently completed fiscal years and any subsequent period

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: ☒ Yes: ☐ (If yes, you must complete the table below)

B. Convertible Debt

The following is a complete list of the Company's Convertible Debt which includes all promissory notes, convertible notes, convertible debentures, or any other debt instruments convertible into a class of the issuer's equity securities. The table includes all issued or outstanding convertible debt at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this Certification.

☐ Check this box to confirm the Company had no Convertible Debt issued or outstanding at any point during this period)

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder. * You must disclose the control person(s) for any entities listed	Reason for Issuance (e.g. Loan, Services, etc.)
SHORT TERM NOTES PAYABLE							
July 2, 2019	\$ 25,000.00	\$ 25,000.00	\$ 25,948.14	Dec. 31, 2025	Non-convertible	Lang Financial Services, Inc., Lanny R Lang, Controlling Shareholder (Officer of Issuer)	Working capital
TOTAL SHORT TERM \$ 25,000.00							
LONG-TERM DEBT							
Sept. 3, 2013	\$ 340,623.00	\$ 1,400,000.00	\$ 49,422.47		Debt and Interest can be used as payment to exercise Warrants, provided however, that Holder shall not exercise Warrants that would increase its ownership of the Issuer to 10% or greater. If there is a balance due at Maturity, Holder shall convert remaining debt and interest into shares of common stock at the fair market price at such time, as reasonably determined by the Issuer in good faith.	Aztoré Capital Corp.; Michael S. Williams, Controlling Shareholder	Investment Banking, Consulting & Capital Advisory Services related to M&A and capital options for funding such mergers & acquisitions.
Aug. 15, 2019	\$ 25,000.00	\$ 25,000.00	\$ 20,674.83	Dec. 31, 2025	Series 2019-A Convertible Note. Convertible into shares of common stock at \$1.12 per share, or can be used as payment of exercise Warrants	SuperEight Capital Holdings, Ltd., Richard Calta, Controlling Shareholder	Working capital
Sep. 19, 2019	\$ 25,000.00	\$ 25,000.00	\$ 20,383.17	Dec. 31, 2025	Series 2019-A Convertible Note. Convertible into shares of common stock at \$1.12 per share, or can be used as payment of exercise Warrants	Kim, Richard C.	Working capital
Sep. 24, 2019	\$ 25,000.00	\$ 25,000.00	\$ 20,341.50	Dec. 31, 2025	Series 2019-A Convertible Note. Convertible into shares of common stock at \$1.12 per share, or can be used as payment of exercise Warrants	Buonincontri, Joseph	Working capital

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder. * You must disclose the control person(s) for any entities listed	Reason for Issuance (e.g. Loan, Services, etc.)
SHORT TERM NOTES PAYABLE							
Nov. 29, 2019	\$ 25,000.00	\$ 25,000.00	\$ 19,791.50	Dec. 31, 2025	Series 2019-A Convertible Note. Convertible into shares of common stock at \$1.12 per share, or can be used as payment of exercise Warrants	Moore, Ray	Working capital
May 31, 2020	\$ 44,000.00	\$ 44,000.00	\$ 32,134.82	Dec. 31, 2025	Series 2019-A Convertible Note. Convertible into shares of common stock at \$1.12 per share, or can be used as payment of exercise Warrants	Lang Financial Services, Inc., Lanny R Lang, Controlling Shareholder (Officer of Issuer)	Conversion of Short-term liabilities
May 31, 2020	\$ 20,000.00	\$ 20,000.00	\$ 14,606.82	Dec. 31, 2025	Series 2019-A Convertible Note. Convertible into shares of common stock at \$1.12 per share, or can be used as payment of exercise Warrants	Quon Moore	Conversion of Short-term liabilities
May 31, 2020	\$ 5,000.00	\$ 5,000.00	\$ 3,651.82	Dec. 31, 2025	Series 2019-A Convertible Note. Convertible into shares of common stock at \$1.12 per share, or can be used as payment of exercise Warrants	Moore JTWROS, Ray & Lorena	Conversion of Short-term liabilities
Nov. 29, 2019	\$ 25,000.00	\$ 25,000.00	\$ 24,754.29	Dec. 31, 2025	Non-convertible	Frederic J. Buonincontri, Officer of Issuer	Working capital
Dec. 30, 2019	\$ 15,000.00	\$ 15,000.00	\$ 14,650.00	Dec. 31, 2025	Non-convertible	Frederic J. Buonincontri, Officer of Issuer	Working capital
Jan. 8, 2020	\$ 8,500.00	\$ 8,500.00	\$ 8,280.19	Dec. 31, 2025	Non-convertible	Frederic J. Buonincontri, Officer of Issuer	Working capital
Feb. 6, 2020	\$ 20,000.00	\$ 20,000.00	\$ 19,216.54	Dec. 31, 2025	Non-convertible	Frederic J. Buonincontri, Officer of Issuer	Working capital
Mar. 3, 2020	\$ 5,000.00	\$ 5,000.00	\$ 4,749.87	Dec. 31, 2025	Non-convertible	Frederic J. Buonincontri, Officer of Issuer	Working capital
Apr. 13, 2020	\$ 5,000.00	\$ 5,000.00	\$ 4,662.37	Dec. 31, 2025	Non-convertible	Frederic J. Buonincontri, Officer of Issuer	Working capital
Aug. 31, 2020	\$ 20,000.00	\$ 20,000.00	\$ 17,491.55	Dec. 31, 2025	Non-convertible	Frederic J. Buonincontri, Officer of Issuer	Working capital
Sept. 17, 2020	\$ 10,000.00	\$ 10,000.00	\$ 8,675.12	Dec. 31, 2025	Non-convertible	Frederic J. Buonincontri, Officer of Issuer	Working capital

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder. * You must disclose the control person(s) for any entities listed	Reason for Issuance (e.g. Loan, Services, etc.)
SHORT TERM NOTES PAYABLE							
Nov. 4, 2020	\$ 9,000.00	\$ 9,000.00	\$ 7,627.50	Dec. 31, 2025	Non-convertible	Frederic J. Buonincontri, Officer of Issuer	Working capital
Nov. 25, 2020	\$ 13,000.00	\$ 13,000.00	\$ 10,903.86	Dec. 31, 2025	Non-convertible	Frederic J. Buonincontri, Officer of Issuer	Working capital
Nov. 25, 2020	\$ 22,000.00	\$ 22,000.00	\$ 18,140.95	Dec. 31, 2025	Non-convertible	Frederic J. Buonincontri, Officer of Issuer	Working capital
May 28, 2021	\$ 18,000.00	\$ 18,000.00	\$ 13,710.00	Dec. 31, 2025	Non-convertible	Frederic J. Buonincontri, Officer of Issuer	Working capital
June 21, 2021	\$ 5,000.00	\$ 5,000.00	\$ 3,760.30	Dec. 31, 2025	Non-convertible	Frederic J. Buonincontri, Officer of Issuer	Working capital
November 30, 2021	\$ 7,500.00	\$ 10,000.00	\$ 5,109.54	Dec. 31, 2023	Non-convertible	Frederic J. Buonincontri, Officer of Issuer	Working capital
TOTAL LONG TERM		692,623					
TOTAL DEBT		\$ 717,623.00					
TOTAL INTEREST			\$ 368,687.15				

4) Issuer's Business, Products and Services

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

House of Jane Inc. ("Issuer") operates through two wholly owned operating subsidiaries; Jane's Brew, LLC and HOJI, LLC.

Jane's Brew, LLC ("JBLLC"). Through JBLLC, Issuer manufactures, sells and distributes a line of products containing cannabinoids derived from federally legal hemp. Since industrial hemp became legal on the federal government level under the 2018 Farm Bill, consumer interest in the potential health benefits of cannabinoids has increased dramatically. The Jane's Brew® line of consumer-packaged dry goods and beverage products provide a convenient way for consumers to purchase and enjoy the benefits of federally legal cannabinoids through the consumption of edibles, tablets and hot and cold beverages. JBLLC sources high-quality, federally legal cannabinoids from HOJI for use in its product line. The Jane's Brew® consumer-packaged dry goods products are distributed online and through retailers.

HOJI, LLC ("HOJI"). Through HOJI, Issuer manufactures, sells and distributes high-quality, water-soluble and federally legal cannabinoid formulated products. These products are marketed under the HOJI™ brand, for use in the Jane's Brew® product line, and to supply other manufacturers of cannabinoid products on a wholesale basis to manufacturers of finished goods products. HOJI also provides contract manufacturing services to third-party brands of federally legal cannabinoid products, including edibles, tablets and powders.

B. List any subsidiaries, parent company, or affiliated companies.

Jane's Brew, LLC ("JBLLC"). Formed November 27, 2018. Single member Arizona limited liability company. Sole member – Issuer. Manager – Frederic J. Buonincontri.

JBLLC has elected to operate as a corporation. Its officers are:

Frederic J. Buonincontri, President and director, rick@hojinc.com

All business activities relating to Jane's Brew® consumer-packaged dry goods and beverage products occur within JBLLC.

HOJI, LLC ("HOJI"). Formed June 6, 2020. Single member Arizona limited liability company. Sole member – Issuer. Manager – Frederic J. Buonincontri.

HOJI has elected to operate as a corporation. Its officers are:

Frederic J. Buonincontri, President and director, rick@hojinc.com

Mano Miyata, General Manager, mano@hojinc.com

All business activities relating to creating and selling high-quality water-soluble cannabinoid formulations occur within HOJI.

C. Describe the issuers' principal products or services.

HOJI™ produces the cannabinoid powder derived from federally legal hemp that is used in all Jane's Brew® product line and numerous manufacturers of finished goods products. The Jane's Brew® products include edibles and beverages infused with cannabinoids.

Regulatory Environment – Arizona

The Company's primary manufacturing operations are located in Arizona. In March 2025, the Arizona Office of the Attorney General issued guidance indicating that the unlicensed sale of THC-infused edible products is prohibited under Arizona law, regardless of federal legality under the 2018 Farm Bill. In addition, a ruling by the Maricopa County Superior Court indicated that certain ingestible hemp-derived products containing intoxicating cannabinoids may fall under Arizona's marijuana regulatory framework.

Although the Company does not currently sell such products within Arizona, it manufactures certain cannabinoid-infused products in the state for distribution into other jurisdictions where such products are permitted. These developments introduce regulatory uncertainty regarding the Company's ability to continue manufacturing certain products within Arizona.

In addition, federal legislation enacted in November 2025 materially narrows the definition of "hemp," with an effective date of November 12, 2026. A significant portion of currently marketed hemp-derived products may not comply with these thresholds and could be classified as controlled substances under upon effectiveness of this new federal law.

The Company continues to manufacture and distribute products containing non-THC cannabinoids, including CBD, CBG, and CBN, which management believes are not subject to these regulatory restrictions.

For additional information, see Notes 1 and 12 in the accompanying financial statements.

5) Issuer's Facilities

JBLLC and HOJI share an approximate 7,500 square foot facility in Tempe, Arizona for its manufacturing, packaging, shipping and receiving, with AXT Nutraceuticals, LLC ("Nutra"). The issuer pays a facility license fee of \$3,000 per month for its use of this shared space. Nutra provides contract manufacturing to HOJI for some of HOJI's products. An officer and director of the Issuer is also the majority owner of Nutra. While Issuer believes its current space is adequate for the near future, there are many larger and available facilities at competitive prices if rapid growth in its operations requires expansion.

6) All Officers, Directors, and Control Persons of the Company

Individual Name (First, Last) or Entity Name	Position/Company Affiliation	City and State	Number of Shares Owned	Class of Shares Owned	Percentage of Class of Shares Owned
Frederic Buonincontri (2)	President, Director, >5% Owner	Phoenix, AZ	6,652,100	Common	55.3%
Lanny R. Lang (3)	Chief Financial Officer (contracted), >5% Owner	Tempe, AZ	651,328	Common	5.90%
Mano Miyata (4)	General Manager, HOJILLC	Phoenix, AZ	600,000	Common	5.2%

Aztoré Capital Corp. Michael S. Williams	>5% Owner	Phoenix, AZ	1,048,300	Common	9.50%
Christopher D. Dewey	>5% Owner	Key Largo, FL	590,300	Common	5.35%

(1) Based on 11,031,895 shares outstanding as of May 31, 2026.

(2) Mr. Buonincontri directly owns 5,456,100 shares and is a beneficial owner of The Aviary, LLC (200,000 shares). Shares and percentages also include 996,000 vested stock options issued pursuant to the Issuer's Equity Incentive Plan and Stock Option Grant Agreement. On April 15, 2024, Mr. Buonincontri pledged all shares of the Company's common stock owned by himself personally to ACC as collateral on a personal loan due from Mr. Buonincontri to ACC. The pledge of assets also includes certain notes payable held by Mr. Buonincontri due from the Company. Due to ACC's ownership interest and financial involvement with the Company, the pledge of these assets could have material implications for the Company. Reference is made to Note 3 of the accompanying unaudited interim consolidated financial statements included in Section 9 of this Report.

(3) Mr. Lang directly owns 474,600 shares in a trust and is beneficial owner of Lang Financial Services, Inc. (176,728 shares).

(4) Shares and percentages include 400,000 vested stock options issued pursuant to the Issuer's Equity Incentive Plan and Stock Option Grant Agreement.

(5) Michael S. Williams is an officer, director and controlling shareholder of ACC and has dispositive control over the shares owned by ACC.

7) Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);
2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;
3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;
4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.
6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

None of the above items 1 to 6 pertain to any Officer or director of the Issuer

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party to or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

8) Third Party Service Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel (must include Counsel preparing Attorney Letters)

Thomas J. Morgan, Esq.
Fennemore Craig, P.C.
2394 E Camelback Rd, Suite 600
Phoenix, AZ 85016
(602) 916-5452
tmorgan@fennemorelaw.com

Accountant or Auditor

None

Investor Relations

None

All other means of Investor Communication:

None

Other Service Providers

Provide the name of any other service provider(s) that assisted, advised, prepared, or provided information with respect to this disclosure statement. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

None

9) Disclosure & Financial Information

A. This Disclosure Statement was prepared by (name of individual):

Name: Lanny R. Lang

Title: CFO

Relationship to Issuer: Officer, >5% owner

B. The following financial statements were prepared in accordance with:

☒ U.S. GAAP

☐ IFRS

C. The financial statements for this reporting period were prepared by (name of individual):

Name: Lanny R Lang

Title: Chief Financial Officer (contracted)

Relationship to Issuer: Officer, >5% owner

Describe the qualifications of the person or persons who prepared the financial statements:

Mr. Lang, 68, has over 40 years of CFO-related restructuring, financial consulting, capital structuring, financial process, and SEC financial reporting experience. Mr. Lang received a Bachelor of Arts degree in Accounting from the University of Northern Iowa in 1980, was a licensed Certified Public Accountant from 1982 until 1986 and practiced accounting with Price Waterhouse (now PwC) from 1980 through 1986. Mr. Lang left public accounting to work in the private sector in 1987 and did not renew his CPA license. Mr. Lang has served as chief financial officer of numerous public and privately held companies since 1992.

Provide the following financial statements for the most recent fiscal year or quarter.

- a. Audit letter, if audited.
- b. Balance sheet.
- c. Statement of income.
- d. Statement of cash flows.
- e. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- f. Financial notes

HOUSE OF JANE INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
- UNAUDITED -

	May 31, 2026	November 30, 2025
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 5,893	\$ 24,162
Accounts receivable	21,302	28,154
Prepaid expenses and other current assets	3,252	3,355
Vendor deposits	23,553	14,867
Inventories	39,171	98,043
Total current assets	93,171	168,581
 Total assets	\$ 93,171	\$ 168,581
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)		
Current liabilities:		
Accounts payable and accrued liabilities	\$ 80,392	\$ 55,936
Accounts payable to related parties	180,932	191,849
Accrued management fees	5,500	5,500
Accrued payroll and payroll taxes	8,179	8,179
Customer deposits	19,320	21,011
Accrued interest payable	148,872	137,892
Accrued interest payable to related parties	219,815	201,398
Notes payable to related party	208,000	208,000
Total current liabilities	871,010	829,765
 Non-current liabilities:		
Notes payable, long-term	340,623	340,623
Convertible notes payable to related parties	44,000	44,000
Convertible notes payable	125,000	125,000
Total non-current liabilities	509,623	509,623
Total liabilities	1,380,633	1,339,388
 Stockholders' deficit:		
Preferred stock - undesignated; 10,000,000 shares authorized	-	-
Common stock, \$.001 par value; 190,000,000 shares authorized, 11,031,895 shares issued and outstanding for both periods	11,032	11,032
Additional paid-in-capital	4,531,941	4,372,341
Accumulated deficit	(5,830,435)	(5,554,180)
Total stockholders' deficit	(1,287,462)	(1,170,807)
Total liabilities and stockholders' deficit	\$ 93,171	\$ 168,581

The accompanying notes are an integral part of these consolidated financial statements.

HOUSE OF JANE INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
- UNAUDITED -

	For the three months ended May 31,		For the six months ended May 31,	
	2026	2025	2026	2025
REVENUES				
Product sales	\$ 76,920	\$ 95,185	\$ 130,366	\$ 208,867
Total revenues	<u>76,920</u>	<u>95,185</u>	<u>130,366</u>	<u>208,867</u>
COSTS OF REVENUES				
Cost of Product sold	36,485	41,273	62,026	77,627
Inventory write-down	50,000	-	50,000	-
Total costs of revenues	<u>86,485</u>	<u>41,273</u>	<u>112,026</u>	<u>77,627</u>
GROSS MARGIN	<u>(9,565)</u>	<u>53,912</u>	<u>18,340</u>	<u>131,240</u>
OPERATING EXPENSES				
General and administrative	68,742	68,125	237,451	241,525
Sales and marketing	7,147	15,274	15,747	34,618
Professional fees	6,000	6,000	12,000	12,000
Total operating expenses	<u>81,889</u>	<u>89,399</u>	<u>265,198</u>	<u>288,143</u>
LOSS FROM OPERATIONS	<u>(91,454)</u>	<u>(35,487)</u>	<u>(246,858)</u>	<u>(156,903)</u>
OTHER INCOME (EXPENSE):				
Interest expense	(14,860)	(14,860)	(29,397)	(29,397)
Total other income (expense)	<u>(14,860)</u>	<u>(14,860)</u>	<u>(29,397)</u>	<u>(29,397)</u>
NET LOSS	<u>\$ (106,314)</u>	<u>\$ (50,347)</u>	<u>\$ (276,255)</u>	<u>\$ (186,300)</u>
BASIC AND DILUTED NET LOSS PER SHARE	<u>\$ (0.010)</u>	<u>\$ (0.005)</u>	<u>\$ (0.025)</u>	<u>\$ (0.017)</u>
BASIC AND DILUTED WEIGHTED AVE. NUMBER OF SHARES OUTSTANDING	<u>11,031,985</u>	<u>11,031,985</u>	<u>11,031,985</u>	<u>11,031,985</u>

The accompanying notes are an integral part of these unaudited financial statements.

HOUSE OF JANE INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT
For the three months ended May 31, 2026
- UNAUDITED -

	Common Stock			Accumulated	
	Shares	Par Value	Paid-in Capital	Deficit	Total
Balance at November 30, 2025	11,031,895	\$ 11,032	\$ 4,372,341	\$ (5,554,180)	\$ (1,170,807)
Stock-based compensation on stock options	-	-	129,600	-	129,600
Net loss	-	-	-	(169,941)	(169,941)
Balance at February 28, 2026	11,031,895	11,032	4,501,941	(5,724,121)	(1,211,148)
Stock-based compensation on stock options	-	-	30,000	-	30,000
Net loss	-	-	-	(106,314)	(106,314)
Balance at May 31, 2026	11,031,895	\$ 11,032	\$ 4,531,941	\$ (5,830,435)	\$ (1,287,462)

The accompanying notes are an integral part of these consolidated financial statements.

HOUSE OF JANE INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT
For the six months ended May 31, 2025
- UNAUDITED -

	Common Stock			Accumulated	
	Shares	Par Value	Paid-in Capital	Deficit	Total
Balance at November 30, 2024	11,031,895	\$ 11,032	\$ 4,047,741	\$ (5,166,257)	\$ (1,107,484)
Stock-based compensation on stock options	-	-	129,600	-	129,600
Net loss	-	-	-	(135,953)	(135,953)
Balance at February 28, 2025	11,031,895	11,032	4,177,341	(5,302,210)	(1,113,837)
Stock-based compensation on stock options	-	-	30,000	-	30,000
Net loss	-	-	-	(50,347)	(50,347)
Balance at May 31, 2025	11,031,895	\$ 11,032	\$ 4,207,341	\$ (5,352,557)	\$ (1,134,184)

The accompanying notes are an integral part of these consolidated financial statements.

HOUSE OF JANE INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
- UNAUDITED -
For the six months ended May 31,

	<u>2026</u>	<u>2025</u>
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net loss	\$ (276,255)	\$ (186,300)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:		
Stock-based compensation on stock options	159,600	159,600
Inventory write-down	50,000	-
Changes in operating assets and liabilities:		
Accounts receivable	6,852	3,301
Prepaid assets and other current assets	103	(1,740)
Vendor deposits	(8,686)	5,603
Inventories	8,872	(35,612)
Accounts payable and accrued liabilities	24,456	9,572
Accounts payable to related parties	(10,917)	42,466
Customer deposits	(1,691)	(32,705)
Accrued interest payable	10,980	10,979
Accrued interest payable to related parties	18,417	18,418
Net cash provided by (used in) operating activities	<u>(18,269)</u>	<u>(6,418)</u>
CASH FLOWS FROM INVESTING ACTIVITIES:		
None	<u>-</u>	<u>-</u>
Net cash provided by (used in) investing activities	<u>-</u>	<u>-</u>
CASH FLOWS FROM FINANCING ACTIVITIES:		
None	<u>-</u>	<u>-</u>
Net cash provided by (used in) financing activities	<u>-</u>	<u>-</u>
NET CHANGE IN CASH	(18,269)	(6,418)
CASH AT BEGINNING OF PERIOD	24,162	30,897
CASH AT END OF PERIOD	<u>\$ 5,893</u>	<u>\$ 24,479</u>
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION		
Cash paid for:		
Interest	<u>\$ -</u>	<u>\$ -</u>
Income taxes	<u>\$ -</u>	<u>\$ -</u>

The accompanying notes are an integral part of these consolidated financial statements.

HOUSE OF JANE INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
- UNAUDITED -
May 31, 2026

NOTE 1 – ORGANIZATION AND OPERATIONS

Current Operations

House of Jane Inc. (the “Company”) was incorporated in Arizona in 2004 and acquired certain intellectual property of the “House of Jane®” and “Jane’s Brew®” brands in 2018. Operations are conducted through two wholly owned subsidiaries, Jane’s Brew, LLC and HOJI, LLC. HOJI manufactures ingestible hemp products, including water-soluble powders, drink mixes, tablets, capsules, and candies, distributed under the Hoji brand, as white-label products, and through contract manufacturing. Jane’s Brew produces and distributes coffees, teas, and other beverages formulated with HOJI’s water-soluble cannabinoid technology.

Regulatory Environment – Arizona Operations

In March 2025, the Arizona Attorney General issued guidance indicating that the unlicensed sale of THC-infused edible products is illegal under Arizona law, even if such products may be permissible under federal law. In addition, a Maricopa County Superior Court ruling held that ingestible hemp-derived products containing THC are subject to Arizona’s marijuana laws and may only be sold through licensed dispensaries.

The Company does not currently sell such products in Arizona but manufactures certain cannabinoid products within the state. These developments introduce uncertainty regarding the Company’s ability to continue manufacturing certain products in Arizona.

In addition, federal legislation enacted in November 2025 materially narrows the definition of “hemp,” with an effective date of November 12, 2026. A significant portion of currently marketed hemp-derived products may not comply with these thresholds and could be classified as controlled substances under upon effectiveness of this new federal law.

The Company continues to manufacture and distribute products containing non-THC cannabinoids, including CBD, CBG, and CBN, which management believes are not subject to these regulatory restrictions.

See Note 10 for additional information regarding potential contingencies associated with these regulatory developments.

Going Concern and Management’s Plans

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. As of May 31, 2026, the Company had a stockholders’ deficit of \$1,287,462 and has incurred recurring losses from operations. For the six months ended May 31, 2026, the Company generated a net loss of \$276,255 and used cash in operating activities of \$18,269.

These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these financial statements are issued.

Management’s plans to alleviate this substantial doubt include obtaining additional capital through equity financings, debt financings, and continued financial support from related parties. The Company has historically relied on advances from officers and related parties to fund

operations and may continue to do so. These plans are not entirely within the Company's control and are dependent on external financing and the continued support of related parties.

There can be no assurance that the Company will be successful in obtaining additional funding or that such funding, if available, will be obtained on terms acceptable to the Company. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). References to the "ASC" hereafter refer to the Accounting Standards Codification established by the Financial Accounting Standards Board ("FASB") as the source of authoritative U.S. GAAP.

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, JBLLC and HOJI. All intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires the Company's management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period.

Making estimates requires management to exercise significant judgment. It is reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future events. Accordingly, the actual results could materially differ from those estimates.

Significant estimates include, but are not limited to, stock-based compensation, valuation of deferred tax assets, inventory valuation, and allowance for expected credit losses.

Inventories

Inventories consist principally of raw materials and finished goods and are stated at the lower of cost or net realizable value using the average cost method. Management periodically evaluates inventories for excess quantities, slow-moving items, and obsolescence. When the estimated net realizable value of inventory is less than its carrying amount, the Company records an inventory write-down through costs of revenues.

During the six months ended May 31, 2026, the Company recorded a non-cash inventory write-down of \$50,000 to reduce certain slow-moving, expired and obsolete inventory to its estimated net realizable value.

Recently Issued Accounting Pronouncements

The Company has evaluated recently issued accounting pronouncements and does not believe that any such pronouncements, if adopted, would have a material effect on its financial statements.

NOTE 3 – NOTES PAYABLE TO RELATED PARTY

An officer of the Company provided a \$25,000 loan to the Company. The maturity date of this loan was December 31, 2025 and is in default. Interest expense on this loan was \$1,870 for each of the six months ended May 31, 2026 and 2025, respectively, and \$945 for each of the three months ended May 31, 2026 and 2025, respectively. Accrued interest of \$25,948 related to this loan is included in accrued interest payable to related parties as of May 31, 2026.

Between 2019 and 2021, the President and sole director advanced an aggregate of \$183,000 to the Company under notes maturing on December 31, 2026. Interest expense on this loan was \$13,878 for each of the six months ended May 31, 2026 and 2025, respectively, and \$7,015 for each of the three months ended May 31, 2026 and 2025, respectively. Accrued interest of \$161,732 is included in accrued interest payable to related parties as of May 31, 2026.

On April 15, 2024, the President pledged these notes and all personally held shares of the Company's common stock, representing approximately 55.3% of the outstanding common stock, as collateral for a personal loan from ACC. Enforcement of the pledge could result in a change of control of the Company.

NOTE 4 – NOTES PAYABLE, LONG-TERM

In September 2013, the Company issued a \$340,623 note payable to Aztoré Capital Corp. ("ACC") as compensation for advisory services. Interest expense on this loan was \$3,397 for each of the six months ended May 31, 2026 and 2025, respectively, and \$1,717 for each of the three months ended May 31, 2026 and 2025, respectively. Accrued interest of \$49,422 is included in accrued interest payable as of May 31, 2026.

The original MOU Note contained certain "Material Acquisition" and "Change of Control" provisions that caused the MOU Note to become due on demand. On November 30, 2018, the Company and ACC entered into a Note Modification Agreement that amended the terms of the MOU Note. Under the Note Modification Agreement: (i) the balance of the MOU Note is due 365 days after the Company files a Form 10 Registration Statement with the SEC (the "New Maturity Date"); (ii) the Company will allow ACC to utilize its debt and accrued interest as payment to exercise Plan Warrants at the published exercise price, subject to the limitation in the Plan Warrants that, when combined with ACC's current beneficial ownership, would increase such ownership of the Company's outstanding shares to 10% or greater (the "10% Limitation"); (iii) until the maturity of the MOU Note, ACC may utilize the principal and accrued interest as payment to exercise other Plan Warrants, subject to the 10% Limitation; and (iv) if there is still a balance due on the New Maturity Date, ACC will exchange the principal and accrued interest then due on the MOU Note for shares of the Company's common stock at the fair market value at such time, as reasonably determined by the Company in good faith.

NOTE 5 – CONVERTIBLE NOTES PAYABLE, LONG-TERM

In 2019, the Company issued \$169,000 aggregate principal amount of Series 2019-A 12% Convertible Notes to accredited investors, maturing on December 31, 2027. These notes are convertible at \$1.12 per share and include anti-dilution provisions. The notes become mandatorily convertible 30 days after the Company's common stock is quoted on OTCQB or the OTC Markets Current Information tier and a Form 10 Registration Statement becomes effective.

An officer holds \$44,000 principal amount of these notes. Interest expense on this loan was \$2,669 for each of the six months ended May 31, 2026 and 2025, respectively, and \$1,349 for each of the three months ended May 31, 2026 and 2025, respectively. Accrued interest of

\$32,135 related to this note is included in accrued interest payable to related parties as of May 31, 2026.

The remaining \$125,000 principal amount is held by unaffiliated parties. Interest expense on this loan was \$7,583 for each of the six months ended May 31, 2026 and 2025, respectively, and \$3,833 for each of the three months ended May 31, 2026 and 2025, respectively. Accrued interest of \$99,450 related to these notes is included in accrued interest payable as of May 31, 2026.

The Company evaluated the embedded conversion features contained in the convertible notes in accordance with ASC 815, *Derivatives and Hedging*, and ASC 470, *Debt*. The Company determined that the conversion features do not require bifurcation as derivative liabilities because they are indexed to the Company's own stock and qualify for the applicable scope exception under ASC 815. The Company also evaluated the convertible instruments for the existence of beneficial conversion features in accordance with ASC 470-20 and determined that no beneficial conversion feature existed as of the issuance dates of the respective instruments. Accordingly, the convertible notes are accounted for as debt instruments.

NOTE 6 – STOCKHOLDERS' DEFICIT

The Company is authorized to issue up to 190,000,000 shares of common stock, par value \$0.001 per share, and 10,000,000 shares of undesignated preferred stock, par value \$0.0001 per share. The Board of Directors has the authority to designate one or more series of preferred stock and to determine the rights, preferences, privileges, and restrictions of each series, including dividend rights, voting rights, conversion rights, and liquidation preferences.

As of May 31, 2026, no shares of preferred stock were issued or outstanding. The Company had 11,031,895 shares of common stock issued and outstanding.

The Company is required to reserve shares of common stock for potential issuance under its equity incentive plan, outstanding warrants, and convertible securities. As of May 31, 2026, a total of 24,251,032 shares were reserved for such purposes.

No shares of common stock were issued during the six months ended May 31, 2026 and 2025.

NOTE 7 – STOCK-BASED COMPENSATION

The Company accounts for stock-based compensation in accordance with ASC 718, *Compensation – Stock Compensation*. The Company's 2019 Omnibus Incentive Plan (the "Plan") authorizes the issuance of up to 3,000,000 shares of common stock. As of May 31, 2026, 1,194,000 shares remained available for future issuance under the Plan.

Restricted Stock Awards

Restricted stock awards ("RSAs") outstanding totaled 150,000 at a weighted average grant date fair value of \$0.50 per share. No RSAs were granted, vested, or forfeited during the six months ended May 31, 2026 and 2025. Accordingly, no stock-based compensation expense was recorded for the periods. As of May 31, 2026, the Company had \$75,000 of unrecognized compensation expense related to non-vested RSAs.

Stock Options

Stock options outstanding totaled 1,806,000 at a weighted average exercise price of \$1.004, of which 1,706,000 were exercisable as of May 31, 2026. No options were granted, exercised, or forfeited during the six months ended May 31, 2026.

The fair value of stock options is estimated at the grant date using the Black-Scholes option pricing model and is recognized as compensation expense over the vesting period. Stock-based compensation expense related to stock options was \$159,600 for each of the six months ended May 31, 2026 and 2025, respectively.

As of May 31, 2026, total unrecognized compensation expense related to non-vested options was \$150,000, which is expected to be recognized over a weighted average remaining vesting period of 1.00 years.

NOTE 8 – COMMON STOCK PURCHASE WARRANTS

As of May 31, 2026, the Company had 23,982,653 warrants outstanding across multiple series with exercise prices ranging from \$4.00 to \$8.00 and expiration dates of August 31, 2026. All outstanding warrants were issued in prior periods, and no warrant activity occurred during the six months ended As of May 31, 2026 and 2025.

The Company evaluated the classification of its outstanding warrants in accordance with ASC 815-40, *Contracts in Entity's Own Equity*. The Company concluded that the warrants meet the criteria for equity classification, as they are indexed to the Company's own stock and do not contain provisions that would require liability classification. Accordingly, the warrants are recorded within stockholders' deficit and are not subsequently remeasured.

The warrants are callable by the Company at \$0.0002 per warrant upon the occurrence of certain conditions as defined in the Warrant Agreement. Management evaluated this provision and determined that it does not preclude equity classification.

The following table summarizes warrant activity by series for the six months ended May 31, 2026:

Series	Warrants Outstanding				Warrants Outstanding	Exercise Price	Expiration Date
	Nov 30, 2025	Granted	Exercised	Forfeited	May 31, 2026		
A	2,923,743	-	-	-	2,923,743	\$4.00	Aug 31, 2026
B	4,211,782	-	-	-	4,211,782	\$4.00	Aug 31, 2026
C & D	8,423,564	-	-	-	8,423,564	\$6.00	Aug 31, 2026
E & F	8,423,564	-	-	-	8,423,564	\$8.00	Aug 31, 2026
Total	23,982,653	-	-	-	23,982,653		

NOTE 9 – RELATED PARTIES

The Company engages in transactions with related parties in the ordinary course of business and accounts for these transactions in accordance with ASC 850, Related Party Disclosures. Related party relationships and transactions are described in:

- Note 3 – Notes Payable to Related Party (short-term loan),
- Note 5 – Notes Payable to Related Party, Long-Term (long-term loans and pledge of assets),
- Note 10 – Commitment and Contingencies (compensation contingencies).

The Company also shares an office suite in a co-working facility with another business controlled by the President and sole director. In addition, HOJI, a subsidiary of the Company, shares an approximately 7,500 square foot warehouse with AXT Nutraceuticals, LLC ("Nutra"), a company majority-owned by the President and sole director. Rent expense was \$19,854 and \$22,854 for the

six months ended May 31, 2026 and 2025, respectively, and \$9,927 for each of the three months ended May 31, 2026 and 2025, respectively.

The Company's products are produced under contract manufacturing arrangements with HOJI. Purchases from Nutra are made on terms equal to or more favorable than those provided to Nutra's other customers. If this relationship were terminated or modified, it could have a material adverse effect on the Company's business, financial condition, and results of operations.

For the six months ended May 31, 2026, purchases from Nutra totaled \$7,186, representing approximately 34% of HOJI's total cost of goods sold. Payments to Nutra during the period were \$37,957 and the Company owed Nutra zero as of May 31, 2026. Offsetting vendor deposits held with Nutra totaled \$11,321 at period end.

For the six months ended May 31, 2025, purchases from Nutra totaled \$43,114, representing approximately 68% of HOJI's total cost of goods sold. Payments to Nutra during the period were \$17,390 and the Company owed Nutra \$25,724 as of May 31, 2025. Offsetting vendor deposits held with Nutra totaled \$1,828 at period end.

NOTE 10 – COMMITMENTS AND CONTINGENCIES

Compensation Contingencies

As part of its consulting agreement with a Company officer who is also its sole director, the Company has agreed, in the event there is a change of control, to a contingent bonus equal to (1) a \$75,000 annual fee plus interest, starting on December 1, 2019, and (2) an incentive fee based on the value of the Company upon a change of control event. As of May 31, 2026, the estimated amount of this contingent obligation was \$483,700. This obligation is contingent upon the occurrence of a future event and has not been recorded as a liability as of May 31, 2026.

Regulatory Environment – Arizona Operations

The Company is subject to regulatory developments in the State of Arizona related to hemp-derived cannabinoid products. In March 2025, the Arizona Attorney General issued guidance indicating that the unlicensed sale of THC-infused edible products is illegal under Arizona law, even if such products may be permissible under federal law. In addition, a Maricopa County Superior Court ruling held that ingestible hemp-derived products containing THC are subject to Arizona's marijuana laws and may only be sold through licensed dispensaries.

While the Company does not currently sell such products in Arizona, it manufactures certain products within the state. As a result, these developments introduce uncertainty regarding the Company's ability to continue manufacturing certain products in Arizona.

In addition, federal legislation enacted in November 2025 materially narrows the definition of "hemp," with an effective date of November 12, 2026. A significant portion of currently marketed hemp-derived products may not comply with these thresholds and could be classified as controlled substances under upon effectiveness of this new federal law.

At this time, the Company is not subject to any enforcement actions. However, management has determined that it is reasonably possible that future regulatory actions could require operational changes, including product reformulation or relocation of manufacturing activities.

The ultimate outcome and potential financial impact of these matters cannot be reasonably estimated at this time.

NOTE 11 – SUBSEQUENT EVENTS

The Company evaluated subsequent events through July 13, 2026, which is the date the financial statements were available to be issued. Other than as described below, no subsequent events have occurred that would require adjustment to or disclosure in the consolidated financial statements.

Subsequent to May 31, 2026, the Company has continued to rely on related party financing and is actively pursuing additional capital through equity and debt financing arrangements to support ongoing operations.

Additionally, the Company continues to monitor regulatory developments related to hemp-derived cannabinoid products (see Note 1 and Note 10).

10) Issuer Certification

Principal Executive Officer:

I, Frederic J. Buonincontri, certify that:

1. I have reviewed this Disclosure Statement of House of Jane Inc.
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Dated: July 13, 2026

/s/ Frederic J. Buonincontri

Frederic J. Buonincontri
President and sole director

Principal Financial Officer:

I, Lanny R. Lang, certify that:

1. I have reviewed this Disclosure Statement of House of Jane Inc.
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Dated: July 13, 2026

/s/ Lanny R. Lang

Lanny R. Lang
Chief Financial Officer (contracted)